Crystals of the urokinase type plasminogen activator βc-uPA in complex with small inhibitors open the way towards structure-based drug design

Journal of Molecular Biology

Volumn 301, Issue 2, 2000, Pages 465-475

  Zeslawska, Ewa ^a   Schweinitz, Andrea ^b   Karcher, Annette ^a   Sondermann, Peter ^a   Sperl, Stefan ^a   Stürzebecher, Jörg ^b   Jacob, Uwe ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Amiloride; Crystal engineering; Crystal structure; Drug design; Urokinase

Indexed keywords

AMILORIDE; BENZAMIDINE; PHENYLALANINE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME INHIBITION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

EID: 0034636986     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.3966     Document Type: Article

References (34)

1. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428
2. The CCP4 suite-programs for protein crystallography
3. ALSCRIPT - A tool to format multiple sequence alignments
4. Crystallography and NMR system - A new software suite for macromolecular structure determination
5. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides
6. Tissue sulfhydryl groups
7. Accurate bond and angle parameters for X-ray protein-structure refinement
8. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride
9. OmpT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification
10. Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane
11. The plasminogen activator system: Biology and regulation
12. A graphics model building and refinement system for macromolecules
13. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
14. MOLSCRIPT - A program to produce both detailed and schematic plots of protein structures
15. Molecular interactions between the urokinase receptor and integrins in the vasculature
16. Raster3D: Photorealistic molecular graphics
17. AMoRe - An automated package for molecular replacement
18. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons
19. Integrins take partners: Cross-talk between integrins and other membrane receptors
20. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors
21. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies
22. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
23. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer
24. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: Implications for the inhibition of factor Xa, tPA, and urokinase
25. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
26. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
27. (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase
28. The crystal-structure of the catalytic domain of human urokinase-type plasminogen-activator
29. Use of bacteriophage-T7 lysozyme to improve an inducible expression system
30. 3-Amidinophenylalanine-based inhibitors of urokinase
31. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor
32. Amiloride selectively inhibits the urokinase-type plasminogen activator
33. Bovine chymotrypsinogen A. X-ray structure analysis and refinement of a new crystal form at 1.8 Å resolution
34. Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli